Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation

Leukemia Research

Volumn 34, Issue 4, 2010, Pages

  Faber, Edgar ^a   Mojzikova, Renata ^a   Plachy, Radek ^a   Rozmanova, Sarka ^a   Stastny, Marek ^b   Divoka, Martina ^a   Jarosova, Marie ^a   Indrak, Karel ^a   Divoky, Vladimir ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; DASATINIB; HYDROXYUREA; IMATINIB; LEUCINE; PHENYLALANINE; PROTEIN TYROSINE KINASE; STEROID;

ADULT; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME PHOSPHORYLATION; GENE MUTATION; HUMAN; HUMAN CELL; LETTER; LYMPHOCYTOSIS; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; WESTERN BLOTTING;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; CYTOGENETIC ANALYSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUCINE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PHENYLALANINE; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-BCR; PYRIMIDINES; THIAZOLES; TREATMENT OUTCOME;

EID: 76749140798     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.09.009     Document Type: Letter

References (8)

1. Jabbour E., Kantarjian H.M., Jones D., Reddy N., O'Brien S., Garcia-Manero G., et al. Characteristics and outcome of patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 112 (2008) 4839-4842
2. Wu J., Meng F., Kong L.Y., Peng Z., Ying Y., Bornmann W.G., et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 100 (2008) 926-939
3. Soverini S., Colarossi S., Gnani A., Castagnetti F., Rosti G., Bosi C., et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 92 (2007) 401-404
4. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
5. Mustjoki S., Ekblom M., Arstila T.P., Dybedal I., Epling-Burnette P.K., Guilhot F., et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23 (2009) 1398-1405
6. Kim D.H., Kamel-Reid S., Chang H., Sutherland R., Jung C.W., Kim H.J., et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 94 (2009) 135-139
7. Sharma S.V., Gajowniczek P., Way I.P., Lee D.Y., Jiang J., Yuza Y., et al. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10 (2006) 425-435
8. Faber E., Nausova J., Jarosova M., Egorin M.J., Holzerova M., Rozmanova S., et al. Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing. Leuk Lymphoma 47 (2006) 1082-1090